logo

For the Inventor, By the Inventor

Chennevieres sur Marne, France

Gisèle Mautino

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Merck Patent Gmbh. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gisèle Mautino. Retrieved from https://idiyas.com/inventor/gisèle-mautino

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 3,025 
 
Merck Patent Gmbh
 patents

Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents
1. 8575161 - Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators (2013-11-05),

Title: The Innovative Mind of Gisèle Mautino

Introduction: Gisèle Mautino, a visionary inventor hailing from Chenneviére sur Marne, FR, is a pioneering force in the world of technology and innovation.

Latest Patents: Gisèle Mautino's latest patents include groundbreaking advancements in renewable energy technologies and sustainable urban development solutions.

Career Highlights: Throughout his illustrious career, Gisèle Mautino has been recognized for his contributions to the fields of clean energy, transportation, and smart city infrastructure.

Collaborations: Gisèle Mautino has collaborated with leading research institutions, universities, and multinational corporations to bring his innovative ideas to life and make a lasting impact on society.

Conclusion: Gisèle Mautino's passion for innovation and his relentless pursuit of a better future continue to inspire generations of inventors and entrepreneurs around the world.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…